Exploring a genetic basis for the metabolic perturbations in ME/CFS using UK biobank

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a clinically heterogeneous disease lacking approved therapies. To assess genetic susceptibility toward a specific metabolic phenotype, we performed a genome-wide association study on plasma biomarker levels (mGWAS) in patients with ME/CFS (<i>n</i> = 875) and healthy controls (HCs) (<i>n</i> = 36,033). We identified 112 significant SNP-biomarker associations in ME/CFS, compared with 4,114 in HCs. Two SNPs specific to ME/CFS, mapping to <i>HSD11B1</i> and <i>SCGN</i>, were associated with phospholipids in extra-large very low-density lipoproteins (VLDLs) and total fatty acids, respectively. Genetic effects of VLDL associations were among the least correlated between ME/CFS and HCs. Heterogeneity tests found differential effects for several lipid traits at <i>ADAP1</i>, <i>NR1H3,</i> and <i>CD40</i>, which are involved in immune regulation. ME/CFS mGWAS summary statistics were decomposed to uncover shared genetic-metabolic patterns, where enrichment analysis highlighted pathways in lipid metabolism, neurotransmitter transport, and inflammation. These findings provide a genetic and molecular rationale for patient heterogeneity and suggest a polygenic predisposition in which many small-effect variants may jointly perturb metabolic mechanisms.